Filing Details
- Accession Number:
- 0001225208-10-006486
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2010-03-02 12:00:00
- Reporting Period:
- 2010-03-01
- Filing Date:
- 2010-03-02
- Accepted Time:
- 2010-03-02 13:17:46
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
901219 | Human Genome Sciences Inc | HGSI | In Vitro & In Vivo Diagnostic Substances (2835) | 223178468 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1191234 | D. Susan Bateson | 14200 Shady Grove Road Rockville MD 20850 | Senior Vice President | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2010-03-01 | 85,200 | $12.56 | 145,558 | No | 4 | M | Direct | |
Common Stock | Disposition | 2010-03-01 | 85,200 | $28.08 | 60,358 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Employee Stock Option - Right to Buy | Disposition | 2010-03-01 | 85,200 | $0.00 | 85,200 | $12.56 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | 2010-04-07 | No | 4 | M | Direct |
Footnotes
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person and Charles Schwab effective 12/10/09.
- This transaction was executed in multiple trades at prices ranging from $27.93 to $28.21. The price reported above reflects the weighted average sale price. Upon written request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price is available.
- These are fully vested and exercisable.